TLR7/8 agonist BM201

An extended-release (ER) microparticle formulation of toll-like receptor type 7 and 8 (TLR 7/8) agonist, with potential immunostimulating and antitumor activities. Upon administration, TLR7/8 agonist BM201 targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.